- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00240097
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin-Etoposide/Carboplatin in Extensive SCLC
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a Phase II, open label study for either chemotherapy-naïve patients with extensive SCLC or patients who are refractory or have relapsed to 1st line therapy for SCLC. The primary objective is to determine the objective response rate.
This study consists of 2 parts:
Part I - Chemotherapy-naïve patients with extensive SCLC
• These patients will be treated with sequential topoisomerase targeting regimens (Regimen A and B). Regimen A consists of irinotecan and oxaliplatin (IROX), given on Day 1, and Neulasta administered on Day 2. Regimen B consists of etoposide and carboplatin, given on Day 15(etoposide will be given daily x 3)and Neulasta on Day 18. Then, Regimen A will be given again 3 weeks later. The first re-evaluation for response will be performed 3 weeks after the second round of the sequential regimens.
Schema of Part I:
Regimen A (→ 2 weeks) Regimen B (→ 3 weeks) Regimen A (→ 2 weeks) Regimen B → (3 weeks) → Re-Stage
- The second re-evaluation for response will be performed 3 weeks after the fourth round of the sequential regimen. At this point patients with stable disease will be observed; those with either a partial or complete response will be treated with another round of sequential therapy (Regimen A → Regimen B) if there is no evidence of unacceptable toxicity. At the end (3 weeks after) of the fifth round of chemotherapy, patients will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks.
- Analysis of Top I and Top II levels in peripheral blood mononuclear cells will be performed in 10 patients of Part I.
- Evaluation of the expression of the ERCC genes (ERCC1, ERCC2, and XPF) will be performed in those patients in Part I with an adequate tumor specimen.
Part II - Patients who have either refractory disease or have relapsed from 1st line therapy
• These patients will be treated with Regimen A1 (IROX) at 3-week intervals. Neulasta will be administered on Day 2 of each cycle. The first re-evaluation for response will be performed 3 weeks after the 3rd cycle of Regimen A1. The second re-evaluation for response will be performed 3 weeks after the 6th cycle of Regimen A1. At this point, patients with stable disease will be observed; those with either a partial or complete response will be treated with two additional cycles of Regimen A1 if there is no evidence of unacceptable toxicity. At the end (3 weeks after) of the 8th cycle of Regimen A1, patients will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks.
Schema of Part II:
Regimen A1 (→ 3 weeks) Regimen A1 (→ 3 weeks) Regimen A1 (→ 3 weeks) Re-Stage
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- University of Alabama at Birmingham
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologic or cytologic diagnosis of SCLC.
- Measurable or assessable tumor parameters.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
- Age between 18 and 79 years (in the State of Alabama > 18).
Adequate bone marrow, liver and renal function, defined as:
- Absolute neutrophil count (ANC) ≥ 1500/µL
- Platelet count ≥ 100,000/µL
- SGOT/SGPT ≤ 2.5 x upper limit of normal or ≤ 5 x upper limit of normal when liver metastases are present.
- Total bilirubin value ≤ 1.5 x upper limit of normal.
- Serum creatinine value ≤ 1.5 x upper limit of normal.
- Fully recovered from any previous surgery (at least 4 weeks since major surgery)
- Must have recovered from prior radiation therapy (at least 3 weeks)
- All participants must agree to practice approved methods of birth control (if applicable). A negative pregnancy test must be documented during the screening period for women of childbearing potential.
Must provide written informed consent and authorization to use and disclose health information (HIPAA).
For Part I
- Extensive-stage SCLC as defined as disease not confined to one hemithorax, including ipsilateral pleural effusion or pericardial effusion.
No prior chemotherapy.
For Part II
- Patients with either refractory disease, or who have relapsed 1st line therapy. No prior chemotherapy with Oxaliplatin or irinotecan.
- Demonstrated tumor progression at the time of study entry.
Exclusion Criteria:
- Concurrent cancer chemotherapy, biologic therapy or radiotherapy.
- Administration of any investigational drug within 28 days prior to administration of the current therapy.
- Symptomatic brain metastases; those patients should be treated first with either whole brain radiation therapy or radiosurgery.
- Concurrent serious infection.
- Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor, which is likely to compromise patient safety and affect the outcome of the study.
- History of other malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for a minimum of 2 years.
- Neuropathy at baseline ≥ Grade 2.
- Any evidence or history of hypersensitivity or other contraindications for the drugs used in this trial.
- History of chronic diarrhea; or diarrhea (excess of 2-3 stools/day above normal frequency) in the past 2 weeks.
- History of a positive serology for human immunodeficiency virus (HIV).
- Psychiatric disorder that prevents patients from providing informed consent or following protocol instructions.
- Pregnant or lactating women.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Irinotecan; Oxaliplatin; Neulasta
Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
|
Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
Andra namn:
|
Experimentell: Etoposide; Carboplatin; Neulasta
Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
|
Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Objective Response Rate (Part I)
Tidsram: baseline to 18 months
|
The primary objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) - IV Large Cell Carcinoma of the Lung with neuroendocrine markers.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Stable response means did not meet criteria for progressive or partical response.
20% progressive disease.
|
baseline to 18 months
|
Response Rate After Relapse
Tidsram: 3 weeks after 3rd cycle of starting therapy after relapse or refractory disease
|
The objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) - IV Large Cell Carcinoma of the Lung with neuroendocrine markers.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Stable response means did not meet criteria for progressive or partical response.
20% progressive disease.
|
3 weeks after 3rd cycle of starting therapy after relapse or refractory disease
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Progression Free Survival (Part I)
Tidsram: baseline to five years
|
Time to progressive disease
|
baseline to five years
|
Overall Survival (Part I)
Tidsram: baseline to 2 years
|
Length of subject survival after starting study treatment
|
baseline to 2 years
|
Samarbetspartners och utredare
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Antineoplastiska medel, fytogena
- Topoisomeras II-hämmare
- Topoisomerasinhibitorer
- Topoisomeras I-hämmare
- Karboplatin
- Etoposid
- Oxaliplatin
- Irinotekan
Andra studie-ID-nummer
- F041222002
- UAB 0421 (Annan identifierare: institutional protocol study number)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Icke-småcellig lungcancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeRefraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Mogen T-cell och NK-cell non-Hodgkin lymfom | Återkommande moget T- och NK-cells non-Hodgkin-lymfom | Återkommande kutant T-cell non-Hodgkin lymfom | Refraktärt kutant T-cell non-Hodgkin lymfomFörenta staterna
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAvslutadLymfom, icke-Hodgkin | Lymfom: Non-Hodgkin | Lymfom: Icke-Hodgkin perifer T-cell | Lymfom: Non-Hodgkin kutant lymfom | Lymfom: Non-Hodgkin Diffus Stor B-cell | Lymfom: Non-Hodgkin follikulära / indolenta B-cell | Lymfom: Non-Hodgkin Mantle Cell | Lymfom: Non-Hodgkin Marginal Zone | Lymfom: Non-Hodgkin...Förenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande kutant T-cell non-Hodgkin lymfom | Steg I Kutant T-cell non-Hodgkin lymfom | Steg II Kutant T-cell non-Hodgkin lymfomFörenta staterna
-
Novartis PharmaceuticalsAvslutadMelanom | Trippel negativ bröstcancer | Anaplastisk sköldkörtelcancer | Andra fasta tumörer | Non-small Sell Lung Cancer (NSCLC)Förenta staterna, Italien, Spanien, Ungern, Taiwan, Tyskland, Nederländerna, Frankrike, Norge, Polen, Thailand, Libanon, Kalkon, Kanada
-
John ReneauAktiv, inte rekryterandeÅterkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Steg III kutant T-cell non-Hodgkin lymfom | Steg IV Kutant T-cell non-Hodgkin lymfom | Primärt kutant anaplastiskt storcelligt lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom | Lymfomatoid... och andra villkorFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)AvslutadAnaplastiskt storcelligt lymfom | Återkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfomFörenta staterna
-
Walter HanelAktiv, inte rekryterandeÅterkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Refraktärt anaplastiskt storcelligt lymfom | T-cell non-Hodgkin lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom och andra villkorFörenta staterna
-
National Cancer Institute (NCI)RekryteringRefraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande transformerat non-Hodgkin-lymfom | Återkommande non-Hodgkin lymfom | Refraktärt non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant... och andra villkorFörenta staterna
-
Mayo ClinicHar inte rekryterat ännuIndolent B-cell non-Hodgkin lymfom | Återkommande indolent non-Hodgkin-lymfom | Refraktärt indolent non-Hodgkin-lymfom | Återkommande indolent B-cell non-Hodgkin lymfom | Refraktärt indolent B-cell non-Hodgkin lymfomFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfomFörenta staterna
Kliniska prövningar på Intervention A: Irinotecan; Oxaliplatin; Neulasta
-
Uppsala UniversityRekryteringKolorektal cancer | Peritoneala metastaserSverige
-
National Cancer Center, KoreaOkändKolorektal neoplasma | Sekundär | MagneoplasmaKorea, Republiken av
-
Imperial College Healthcare NHS TrustImperial College LondonAvslutadBröstcancer | BröstsjukdomStorbritannien
-
German Institute of Human NutritionBeneo GmbHAvslutadDiabetes mellitus, typ 2 | Metaboliskt syndromTyskland
-
Nanyang Technological UniversitySheffield Hallam University; Université de Montréal; National Gallery Singapore...Avslutad
-
Hallym University Medical CenterPfizer; HK inno.N Corporation; Handok Inc.; Jeil Pharmaceutical Co., Ltd.AvslutadGastrointestinala neoplasmerKorea, Republiken av
-
Medical University of ViennaRekryteringEsophageal AchalasiaÖsterrike
-
Peking Union Medical College HospitalHar inte rekryterat ännuBorderline resektabel pankreascancer
-
University of PisaAzienda Ospedaliero, Universitaria Pisana; IRCCS Fondazione Stella MarisAnmälan via inbjudan